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A murine leukemia virus-derived replication-competent retroviral vector with a translational cassette for the enhanced
green fluorescence protein (EGFP) was previously found to function efficiently in cell culture (Jespersen et al., 1999, Gene
239, 227–235). We here report that infection of newborn NIH Swiss mice gives rise to EGFP expression in a majority of spleen
cells within the first days after infection. Among the nonadherent spleen cells, B, T, and NK lymphocytes were found to be
efficiently marked by EGFP by flow cytometry analysis, whereas the adherent spleen cells were negative in most animals.
Analysis at time points up to 60 days after infection reveals a decline in EGFP-positive spleen cells over time. Viremia analysis
and PCR analysis of spleen DNA indicate that viruses that have lost the translation cassette predominate at later stages. The
results provide a model for efficient gene delivery to spleen cells in a time window of 1 to 2 weeks after infection of newborns.
Although this type of vector will not in itself be applicable in the clinic, we envision that efficient in vivo gene delivery will be
valuable by analysis of differentiation and proliferation of hematopoietic cells in animal models and by development and
evaluation of effectors interfering with these processes. © 2002 Elsevier Science (USA)INTRODUCTION
Replication-defective retroviral vectors are widely
used for ex vivo gene transfer. For clinical applications,
ex vivo protocols offer the means of monitoring and
controlling for the appearance of replication-competent
retroviruses that may emerge as a result of recombina-
tion events and compromise safety (Farson et al., 1999).
Generally, ex vivo gene transfer schemes suffer from low
gene transfer efficiency and additional steps may be
needed to enrich for transduced cells in the transplant
(Journal of Gene Medicine Web site). In cases where the
transferred gene offers a direct selective advantage in
the recipients, engraftment and proliferation may be fa-
vored (Parkman et al., 2000). However, in other cases
engraftment of the genetically modified cells is disfa-
vored and may require treatments leading to cell reduc-
tion or immunosuppression of recipients prior to trans-
plantation.
As an alternative possibility, in vivo gene delivery may
lead to a higher overall efficiency. By injection of irradi-
ated retroviral producer cells into the bone marrow cavity
of rabbits, Nelson et al. (1979) obtained in vivo gene
1 To whom correspondence and reprint requests should be ad-
dressed at Department of Molecular and Structural Biology, University© 2002 Elsevier Science (USA)
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328transfer into multiple hematopoietic lineages at percent-
ages comparable to those achieved by ex vivo transduc-
tion. By this procedure, gene delivery into the local he-
matopoietic environment but not into adjacent tissues
was demonstrated. In vivo gene delivery by retroviral
vectors undergoing multiple rounds of replication in the
tissues of the recipient represents another way to
achieve increased efficiency of gene transfer. Efficient in
vivo delivery by replication-competent retroviral vectors
might be of significant value in the dissection of differ-
entiation and proliferation signals as well as for the
testing and optimizing of effectors toward their potential
later use in a clinically accepted gene transfer vehicle.
However, an immune response against a vector-en-
coded protein(s) may prevent efficient spread of the
vector in the tissues of the host, and this approach may
be feasible only in immunocompromised animals or un-
der conditions of tolerance such as in infected newborn
mice (Sarzotti et al., 1996).
We previously reported on replication-competent vec-
tors based upon the Akv murine leukemia virus (MLV)
(Jespersen et al., 1999) capable of productively replicat-
ing in mammalian cells as opposed to replication-com-
petent vectors derived from avian viruses (Zheng and
Hughes, 1999). In this vector design, a cassette compris-Key Words: murine leukemia virus; in vivo gene delivery;
lymphocytes.
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ing an internal ribosome entry site (IRES) and a heterol-
ogous gene was inserted into the upstream part of theongreen
U3 region of the long terminal repeat (LTR). Vectors of
this type were reported to replicate for several rounds in
cell culture. Here we analyze the ability of an enhanced
green fluorescent protein (EGFP) gene containing a vec-
tor of this type to deliver genes to hematopoietic cells
after infection of newborn mice and report that more than
50% of the spleen cells are marked by EGFP during the
first days after infection.
RESULTS AND DISCUSSION
Gene transfer in mice
AkvU3-EGFP is a replication-competent MLV that har-
bors a translational cassette consisting of the IRES of
encephalomyocarditis virus and the EGFP coding region
inserted in U3 (Fig. 1). To determine whether AkvU3-
EGFP can propagate in vivo, 3- to 4-day-old NIH Swiss
mice were infected intraperitoneally with 104 colony-
forming units (CFU) of AkvU3-EGFP and spleen cells
were analyzed for EGFP expression at different time
points postinfection. In parallel experiments, spleen cells
from mice infected with Akv MLV were used as a nega-
tive control. Three separate experiments with AkvU3-
EGFP were carried out with similar outcomes. For the
sake of simplicity, the data for only one of them are
presented here. Mononuclear cells were purified and
EGFP expression was assessed in the total fraction of
nonadherent spleen cells (Fig. 2, left column). Whereas
no EGFP-positive cells were detected on day 1, more
than 50% of cells were EGFP-positive on day 4 and
approximately 50% on day 7. After day 7, the percentage
of EGFP-positive cells dropped to near detection levels.
To assess which spleen cells were infected, pheno-
typic identification of specific lineages was obtained
using phycoerythrine (PE)-conjugated antibodies di-
rected against specific cell surface antigens on T lym-
phocytes (CD 3), B lymphocytes (CD 19), and NK lympho-
cytes (Pan NK) (Fig. 2, middle column). In no case did the
sum of the percentages of EGFP-positive B, T, and NK
cells equal 100% of the EGFP-positive cells, indicating
that other cell types not recognized by the B, T, and NK
cell-specific antibodies are infected by AkvU3-EGFP. The
phenotypic characterization of these cells was not un-
dertaken. However, at days 4 and 7, when EGFP-positive
nonadherent spleen cells were abundant, no EGFP-pos-
itive cells were detected among the adherent spleen
cells (Fig. 2, right column).
An example of variation among animals in the pattern
of EGFP expression is provided by the mouse of litter 1
analyzed at day 30. On day 12, EGFP expression had
decreased to around 1% of nonadherent spleen cells in
the two litters studied. Nevertheless, at day 30, the
mouse from litter 1 presented 12% EGFP-positive nonad-
herent spleen cells and in addition this is the only animal
which presented adherent EGFP-positive spleen cells
(18%).
B, T, and NK spleen cells during infection
Most MLVs are pathogenic, at least in some strains of
mice. Akv MLV, the parental virus of the vector used in
the present study, has been reported to induce B-cell
lymphomas with a latency period of around 1 year (Lov-
mand et al., 1998). An effect of MLV infection on the
composition of spleen cells 6 to 10 weeks after infection
has been reported (Davis et al., 1987; Storch et al., 1985).
To study the effects of genes delivered by replication-
competent MLVs, it is therefore important to monitor the
effect of virus infection per se also during the first weeks
after infection.
Flow cytometry analysis allowed quantification of the
total spleen B, T, and NK cell populations as well as that
of EGFP-positive cells in each subpopulation (EGFP-
positive B, T, and NK subpopulations as the percentage
of the total nonadherent spleen cells). The histograms in
Fig. 3 show the percentages of the total B, T, and NK
population (first bar), the B cell population (second bar),
the T cell population (third bar), and the NK population
(fourth bar) for noninfected, Akv MLV-infected, and
FIG. 1. A schematic representation of the AkvU3-EGFP replication-competent vector and the parental wild-type Akv virus. Underlined sequences
are CelII restriction enzyme recognition sites. Wide boxes, Akv LTR sequences. Thin boxes, the IRES-EGFP cassette with polylinkers. Polylinker at
the CelII IRES junction: TGCAGATGCATGGCCCATGCGGCCGC. Polylinker at the EGFP CelII junction: AGCGGCCGTACGCGTCATATG. PPT, polypurine
tract.
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FIG. 2. Flow cytometric analysis of spleen cells. Mononuclear cells were purified from the spleen at various time points after infection by Akv MLV,
AkvU3-EGFP, or NaCl solution. (Left column) Nonadherent spleen cells were analyzed for EGFP expression by flow cytometry. (Middle column) The
phenotype of EGFP-expressing cells was determined by flow cytometry analysis using monoclonal antibodies specific for cell type-specific
differentiation markers. For simplicity, only flow cytometry profiles are shown for litter 1; results for both litters are given in the upper right-hand
corners. (Right column) Adherent spleen cells were analyzed for EGFP expression by flow cytometry. EGFP-negative mononuclear cells were purified
from Akv MLV-infected animals and PE-negative mononuclear cells were derived by incubation with non-PE-conjugated antibody.
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AkvU3-EGFP-infected animals. Analysis at day 1 postin-
fection revealed no difference in B, T, and NK cell pop-
ulations of infected and noninfected animals. However,
B  T  NK cell populations from animals infected by
Akv MLV or AkvU3-EGFP decreased at day 4 (40–45%)
and day 7 (30–35%) as compared with the population of
noninfected animals (60%), with T and NK cells being the
most affected. At later time points, the differences be-
tween infected and noninfected animals disappear, pos-
sibly with some delay for the NK cell population. Our data
do not allow us to conclude whether these numbers
reflect a true decrease in lymphoid cells or rather an
increase in other cell types attracted by the infection
(macrophages, dendritic cells, etc.).
In accordance with Fig. 2, EGFP-positive cells are
most abundant at days 4 and 7 (gray bars). For AkvU3-
EGFP-infected animals, almost all B, T, and NK cells are
EGFP-positive at day 4 postinfection and then EGFP
expression decreases.
Vector stability
Blood viremia was monitored using both an EGFP
fluorescence-based assay and a focal immunofluores-
cence assay (FIA) of viral envelope proteins. In both
cases, titers were expressed as colony-forming units per
milliliter (Table 1). Viremia was never detected in nonin-
fected animals nor at day 1 postinfection in Akv MLV- or
AkvU3-EGFP-infected animals. EGFP-expressing viruses
were detected in the blood at day 4, rose to 60-fold
higher levels at day 7, and finally fell to undetectable
levels at day 60 postinfection. Nevertheless, by FIA the
presence of viruses could be detected until the end of
the experiment in all infected animals. In Akv MLV-in-
FIG. 3. Percentage of B, T, and NK cells among nonadherent cells from spleens of infected and noninfected animals. The percentage of B, T, and
NK cells was determined by flow-cytometry and analyzed using the Cell-Quest software. The percentage of EGFP-positive cells was determined from
the data presented in Fig. 2.
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fected animals, viremia, as assayed by FIA, was detected
in all cases after day 4 postinfection and remained con-
stant over 60 days.
To detect proviral DNA in the spleen, a PCR assay was
employed. Two primers which permit the amplification of
a fragment of 651 bp from wild-type Akv proviruses and
one of 1983 bp from AkvU3-EGFP proviruses were uti-
lized on a set of purified spleen DNA samples (Fig. 4).
DNA from NaCl-injected (noninfected) control mice gave
rise to a single PCR band that, after being subcloned in
pGEMT-Easy and being sequenced, revealed an endog-
enous retroviral sequence differing from Akv MLV by one
point mutation and lack of tandem repeats of the U3
(data not shown). In DNA samples from AkvU3-EGFP-
infected mice, three bands were identified by subcloning
and sequencing of several samples. The fastest migrat-
ing band found at early days after infection again corre-
sponds to the endogenous virus band of the control
samples. The band migrating slightly slower contained
wild-type Akv MLV sequences and the slowest band
contained Akv MLV sequences with the IRES-EGFP in-
sert. For all three bands, sequences obtained at different
days postinfection were identical. For the day 4 and day
7 samples of AkvU3-EGFP-injected mice, the IRES-EGFP-
containing band was predominant, whereas the Akv MLV
wild-type band was more intense at day 12. For day 30
and day 60, only the Akv wild-type band was detected. By
using one EGFP-specific primer and the primer located
in env, we were able to amplify PCR bands correspond-
ing to the expected size for a complete IRES-EGFP cas-
sette from all DNA samples from spleens. However, the
bands from day 60 and day 30 were not as intense as
samples of earlier time points, indicating that the level of
intact AkvU3-EGFP had dropped.
In our earlier studies in cell culture, multiple passages of
this type of replication-competent vector led to the appear-
ance of variants with deletions in the heterologous gene
cassette and, eventually, to the dominance of these deletion
variants with presumed better replication fitness. After elim-
ination of the initially Akv-EGFP-infected spleen cells, new
cells may be infected by viruses that have already lost the
EGFP cassette. Considering that cells of the spleen are
known to turn over rapidly (Rolink et al., 1998) the in vivo
pattern may comply with our earlier in vitro observations.
Moreover, receptor interference will prevent superinfection
by EGFP-harboring vectors of cells already infected by a
cassette deletion variant. Without a specific selective pres-
sure operating in favor of maintaining the transgene in the
vectors or in the cells, the problem of the appearance of
deletion variants with a replication advantage will persist.
The results reported here show some animal to animal
variations with respect to transgene expression. One ani-
mal analyzed at day 30 after infection showed 12% EGFP-
positive cells among the nonadherent spleen cells while a
second animal showed none. The latter animal was also
the only one that showed significant EGFP expression in
adherent spleen cells. A similar animal to animal variation
was seen in a second experiment (data not shown).
TABLE 1
Assay of Blood Viremia
Days postinfection
1 4 7 12 30 60
83A25a EGFPb 83A25a EGFPb 83A25a EGFPb 83A25a EGFPb 83A25a EGFPb 83A25a EGFPb
Akv MLV-infected
animals
— — 0.6 104 — 5.5 105 — 5.0 105 — 2.0 105 — 6.7 104 —
— — 1.8 104 — 6.5 105 — 4.0 105 — 2.0 105 — 8.2 104 —
AkvU3-EGFP-infected
animals (litter 1)
— — 5.0 103 2.0 103 9.5 104 5.8 104 5.7 104 1.0 101 1.1 105 1.2 103 2.0 104 —
— — 5.0 103 1.0 103 4.5 104 2.2 104 4.3 104 1.6 101 1.1 105 1.8 103 2.0 104 —
AkvU3-EGFP-infected
animals (litter 2)
— — 7.5 103 2.0 103 1.2 105 8.0 104 1.0 105 3 101 7.0 104 0.1 101 6.6 104 —
— — 6.5 103 2.0 103 0.8 105 1.0 105 1.0 105 1.6 101 5.0 104 0.3 101 4.4 104 —
Note. One mouse per group was sacrificed at regular intervals and viremia was assayed in duplicate (CFU/ml). Viremia was not detected in
noninfected mice.
a Cells infected by either EGFP-expressing or non-EGFP-expressing viruses were assayed by FIA using a specific anti-envelope glycoprotein 83A25
monoclonal antibody.
b Cells infected by EGFP-expressing retroviruses were assayed using direct EGFP fluorescence.
FIG. 4. PCR amplification from spleen DNA of provirus sequences
containing the IRES-EGFP insert. Lane C corresponds to control DNA
from mice injected with a NaCl solution. Lanes 1 and 2 correspond to
litters 1 and 2, respectively.
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Perspectives
Vehicles for stable transfer of genes into hematopoi-
etic cells are derived mainly from retroviruses of the MLV
group. Even though the tumorigenic specificity of individ-
ual strains may be narrower the MLVs are able to infect
a broad range of hematopoietic cells. Using EGFP as a
reporter gene and the spleen as a read-out organ, the
present study reports on efficient gene delivery into
mouse hematopoietic cells in vivo. The EGFP gene is
delivered by an Akv MLV-based vector that harbors all
genes needed for viral replication and is able to undergo
multiple rounds of infection in the animal.
Despite the appearance of wild-type viruses at later
stages and the need to assess possible effects caused
by the viruses, the gene delivery model presented here
should be valuable for studying the effect of transgene
expression in spleen cells in a time window of 1 to 2
weeks. Moreover, improvements in the vector and deliv-
ery scheme may result in the prolongation of the time
window of efficient transgene expression. A model for
efficient in vivo gene delivery may serve a number of
research applications in which efficiency of gene deliv-
ery rather than site-specific or time-controlled expres-
sion is of importance. Among these are applications in
relation to the development of gene transfer systems,
analysis of the function of a gene product in an in vivo




NIH3T3 cells were grown in Dulbecco’s modified Ea-
gle’s medium (DMEM) containing Glutamax-1 (Gibco)
supplemented with 10% newborn calf serum and 1%
penicillin/streptomycin (Gibco). BOSC 23 (Pear et al.,
1993) andMus dunni embryo fibroblast cells were grown
in DMEM containing Glutamax-1 and supplemented with
10% fetal calf serum. Prior to transfection, the BOSC 23
cells were selected in HAT medium as described (Jes-
persen et al., 1999).
Vectors
AkvU3-EGFP is isogenic to the previously described
AkvBi-EGFP (Jespersen et al., 1999) except that the spacer
sequence from the 3 end of the IRES element, IRES start
codon 10 (codon in parentheses), to the translational start
codon of the EGFP gene has been changed from
(ATT)GCCGCGTGTGGCCTCGAACACCGAGCGACCCTGC-
AGCCGCGGTCGACATGG to the spacer proposed by Mor-
gan et al. (1992), (ATA)ATACCATG. As assayed by flow
cytometry analysis, AkvU3-EGFP was found to express
EGFP at a 10-fold higher level than the original AkvBi-EGFP
construct. The AkvU3-EGFP producer line was generated
as described by Jespersen et al. (1999) and expanded in
cell culture, and aliquots were stored in liquid nitrogen.
Virus harvested from these cells was used for injection of
mice.
Assay of viruses
Production and titer assays of Akv MLV and AkvU3-
EGFP stocks were carried out as follows. Virus-produc-
ing cells were cultured at confluence for 3 days. Viral
supernatants were harvested and filtered through 0.45-
m-pore-size filters and serial dilutions were added in
duplicate toM. dunni cells seeded at a density of 2 103
cells/well of 96-well plates (Nunc, Roskilde, Denmark)
the day before in the presence of 8 g/ml polybrene. The
culture medium was changed on the following day and,
when confluent, cells infected by AkvU3-EGFP were
scored using direct EGFP fluorescence and cells in-
fected by Akv MLV were scored by FIA (Sitbon et al.,
1985) using the specific anti-envelope glycoprotein
83A25 monoclonal antibody (Evans et al., 1990). The
antibody was revealed using an anti-mouse immuno-
globulin fluorescein isothiocyanate-conjugated rabbit
antiserum (Sigma, St. Louis, MO).
Viremia
Blood viremia was determined by duplicate infections
of M. dunni cells using serial dilutions of infected animal
sera in the direct EGFP fluorescence assay and the
indirect focal immunofluorescence assay.
Mice and viral infection
NIH Swiss mice were purchased from CERJ (France).
Animals were maintained with their mother for up to 3
weeks of age. Two litters of 3- or 4-day-old animals were
injected intraperitoneally with 100 l of AkvU3-EGFP (1
105 CFU/ml) and animals from 1 litter were injected
intraperitoneally with 100 l (1  105 CFU/ml) of Akv
MLV. Finally, noninfected mice were used as a control.
Mice were bled for determination of viremia; then, the
spleen was removed for DNA preparation and for purifi-
cation of mononuclear cells.
Flow cytometry
For isolation of mononuclear cells, spleens were ex-
cised and pooled using six spleens of each litter at day
1 postinfection, four spleens of each litter at day 4 postin-
fection, and two spleens of each litter at days 7 and 12.
One spleen was used at days 30 and 60 postinfection.
Spleens were placed in a petri dish with 10 ml of RPMI
medium and crushed with a 1-ml syringe (piston) and
then splenocytes were detached by pipetting up and
down. Cells were centrifuged at 490 g at 18°C for 5 min
and the pellet was resuspended in RPMI medium (Gibco)
plus erythrocyte lysis buffer (32  106 M EDTA, 0.15 M
NH4Cl, 0.01 M KHCO3). After centrifugation at 490 g at
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18°C for 5 min, cells were incubated at 37°C in the
presence of 5% CO2 for 2 h, to remove adherent cells
essentially, including dendritic cells and macrophages.
Cells in suspension were centrifuged and resuspended
in 8 ml of Hanks’ balanced salt solution (BioWhittaker
Europe) containing phenol red and 4 ml of Ficoll solution
(Ficoll-Paque Plus, Amersham) at room temperature. The
mixture was centrifuged at 330 g at 18°C for 20 min and
lymphocytes were collected from the interphase and
washed, first, with 40 ml of PBS (0.15 M NaCl, 0.01 M
sodium phosphate, pH 7) and then twice with 30 ml of
RPMI medium. Monoclonal (PE)-conjugated anti-mouse
CD3, anti-mouse CD19, and anti-mouse PAN NK (Pharm-
ingen) were used to assay for the percentages of B, T,
and NK cells, respectively, in the spleen of infected and
noninfected animals by flow cytometry using a FACScan
flow cytometer (Becton Dickinson, Mountain View, CA).
EGFP-positive cells were detected by direct fluores-
cence flow cytometry. Ten thousand cells were analyzed
per experiment. Green fluorescence (EGFP) was mea-
sured through a 530-nm/30-nm bandpass filter and or-
ange fluorescence (PE) was measured through a 585-
nm/42-nm bandpass filter after illumination with an ar-
gon ion laser tuned at 488 nm. Lymphocytes (B, T, and
NK) were incubated with specific antibodies for 30 min at
4°C and then washed in PBS before flow cytometry
analysis.
PCR
DNA was isolated from spleens as previously de-
scribed (Gross-Bellard et al., 1973). PCR amplification
was performed in 25 l PCR buffer containing 100 to 400
ng of purified spleen DNA, 25 pmol of each primer, 0.2
mM dNTPs, and 0.5 U of AmpliTaqGold DNA polymerase
(Perkin–Elmer). After an initial AmpliTaqGold activation
step of 9 min at 94°C, the PCR was as follows: 40 cycles
of 1.2 min at 94°C, 1.2 min at 60°C, and 3 min at 72°C.
The 40 cycles were followed by an incubation of 7 min at
72°C. The two oligonucleotides used as primers match
sequences located outside the IRES-EGFP insert at the
3 end of the envelope gene (position 7562 to 7590,
CAACAAGGGTGGTTTGAAGGGCTGTTTAA) of the Akv
MLV RNA genome and in the U3 region (position 8185 to
8213, AGGCTTGGGGTTGATCCCCGGTCATCTGG) (Van
Beveren, 1985). These two primers amplify a DNA frag-
ment of 651 bp from wild-type Akv MLV and a fragment of
1983 bp from AkvU3-EGFP.
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